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subunit alter NMDA receptor ligand binding and
ion channel properties
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Genetic and bioinformatic analyses have identiﬁed missense mutations in GRIN2B encoding
the NMDA receptor GluN2B subunit in autism, intellectual disability, Lennox Gastaut and
West Syndromes. Here, we investigated several such mutations using a near-complete,
hybrid 3D model of the human NMDAR and studied their consequences with kinetic mod-
elling and electrophysiology. The mutants revealed reductions in glutamate potency;
increased receptor desensitisation; and ablation of voltage-dependent Mg2+ block. In addi-
tion, we provide new views on Mg2+ and NMDA channel blocker binding sites. We
demonstrate that these mutants have signiﬁcant impact on excitatory transmission in
developing neurons, revealing profound changes that could underlie their associated neu-
rological disorders. Of note, the NMDAR channel mutant GluN2BV618G unusually allowed
Mg2+ permeation, whereas nearby N615I reduced Ca2+ permeability. By identifying the
binding site for an NMDAR antagonist that is used in the clinic to rescue gain-of-function
phenotypes, we show that drug binding may be modiﬁed by some GluN2B disease-causing
mutations.
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N-methyl-D-aspartate-receptors (NMDARs) are ionotropicglutamate receptors (iGluRs) that form a cornerstone offast excitatory neurotransmission in the brain1. They are
composed of homologous subunits selected from three sub-
families with multiple members: GluN1 (with 8 alternatively
spliced isoforms), GluN2 (four subtypes, A-D) and GluN3 (two
subtypes, A and B). Moreover, the subunit composition strongly
affects NMDAR pharmacological and biophysical proﬁles2.
Although GluN1 is ubiquitously expressed throughout the brain,
GluN2 subtypes show spatial and temporal differentiation.
GluN2A and GluN2C are expressed mainly after birth, whereas
GluN2B and GluN2D predominate early during development
with restricted expression in the mature brain3. NMDARs have
critical roles in synaptogenesis, brain plasticity and higher cog-
nitive function4. Given their broad physiological importance, it is
unsurprising that NMDAR dysfunction, as a result of pathogenic
mutations, is associated with neurological and psychiatric dis-
orders such as epilepsy, intellectual disability and autism-
spectrum disorders5–9.
To understand the consequences of NMDAR mutations on
neuronal activity, here we have studied a range of de novo mis-
sense mutations affecting the GluN2B subunit, subsequently
proﬁling four in detail, C461F, P553L, N615I and V618G, which
are associated with neurodevelopmental disorders in children5,6,9.
These mutations were selected because of bioinformatic predic-
tions of pathogenicity, and because they are structurally diverse,
involving functionally important domains in NMDARs. In
addition, we wanted to explore potential links between NMDAR
dysfunction and clinical phenotypes. Notably, C461F features in
an individual with Lennox Gastaut syndrome with autistic fea-
tures5; P553L was present in another subject with severe intel-
lectual disability9; and N615I and V618G both associate with
West syndrome6.
We investigated how these mutations affected the structure and
function of NMDARs in vitro before examining how excitatory
transmission was perturbed in situ. In doing so, we uncovered
differential effects of the ion channel mutants on Mg2+ and Ca2+
permeability, providing new insight into Mg2+ and memantine
binding sites in the channel, and how mutations alter NMDAR
kinetics to affect excitatory transmission. Finally, we explored the
binding site, mechanism of action and therapeutic potential of the
NMDAR antagonist memantine, a drug that has been approved
for use in humans by regulatory agencies such as the Medicines &
Healthcare products Regulatory Agency. Our ﬁndings open the
possibility that memantine could be used for some individuals
with neurological conditions resulting from GluN2B mutations.
Results
Bioinformatics of disease-causing NMDAR mutations. We
examined 13 mutations in GluN2B that associate with neurode-
velopmental disorders (Supplementary Table 1). From these we
selected nine, predicted to be pathogenic from bioinformatics
analysis, for a broad screen of recombinant NMDAR properties
in HEK293 cells. These mutations were located to domains of
GluN2B NMDARs, and their effects on glutamate potency, cur-
rent density, and how they affected the current–voltage rela-
tionship were examined (Supplementary Table 2). Subsequently,
four mutations (C461F, P553L, N615I and V618G) were selected
for detailed investigation based on their diverse locations within
the NMDAR and because of their profound effects on receptor
function (Supplementary Table 2).
Generating a 3D model of the human NMDAR model. To
provide a structural framework for precisely locating the selected
GluN2B mutations, we generated a hybrid model of a human
tetrameric NMDAR (GluN1–GluN2B) (Figs. 1a and 2a). To do
so, we used several templates provided by crystal structures of rat
and Xenopus GluN1–GluN2B NMDARs10,11. In these templates,
to facilitate crystallisation of the NMDAR structure, some domain
linkers were removed. Although these missing linkers were
retained in recent cryo-EM structures of NMDARs12,13 the
associated atomic models could not be used as templates because
of their lower resolution (~7 Å;12, 10–15 Å;13, when compared to
the 3.7 Å; (frog)10 and 4 Å; (rat)11 resolution for the X-ray
structures). Also the cryo-EM structures were captured in pre-
open/desensitised or inhibited states, whereas our primary aim
was to obtain a structure in a trapped state to investigate Mg2+
and memantine binding. Our hybrid NMDAR model closely
aligns with the pore region of the Xenopus laevis structure (PDB
4TLM; Supplementary Fig. 1) that is considered to reside in a
trapped conformation following co-crystallisation with the
NMDA channel blocker, MK-80110.
To build a ‘near-complete’ hybrid model, we reinserted the
absent linkers in conjunction with those domains provided by the
individual NMDAR crystal structures. In our model, only the
M1-M2 intracellular loop and the C-terminal domain (CTD) of
each subunit are absent, which are also missing in the Xenopus
and rat NMDAR crystal structures. This new molecular build
provides one of the most complete models for the human
GluN1–GluN2B tetramer.
For the selected GluN2B mutations, C461 is located in S1 of the
ligand binding domain (LBD), close to the orthosteric glutamate
binding site formed by H486, R519, S690, Y731, D732 and Y762
(Fig. 1b, c; Supplementary Fig. 2c–e). By contrast, P553 was
located at the extracellular end of the ﬁrst transmembrane
domain, M1 (pre-M1) (Fig. 1d; Supplementary Fig. 2a). This
region is considered, by the nature of its residues14, to form a
‘hydrophobic box’ involved in NMDAR gating. The hybrid model
indicates that P553 is adjacent to the highly conserved nine
residue signal-transduction element, -SYTANLAAF-, in M3 of
the same subunit (Supplementary Fig. 2a, b), which is involved in
coupling ligand binding to ion channel gating15. The ﬁnal two
selected residues, N615 and V618, are located in the M2–M3
linker, which forms part of the ion channel lining. Asparagine 615
is found just above the narrowest constriction in the pore and is
associated with the juxtaposed N616 of the GluN1 subunit;
Fig. 1e). By contrast, V618 was located deeper in the pore, with a
side-chain rotated away from the lumen, interacting with residues
in M2 and M3 of GluN1, and with the M2–M3 linker in GluN2B
(Fig. 1e; Supplementary Fig. 2f).
Impact of GluN2B mutations on glutamate potency. We ﬁrst
assessed the effect of the mutations on glutamate potency by
generating concentration–response curves for GluN1–GluN2B
NMDARs in HEK293 cells. We used the alternatively spliced
GluN1–4b isoform for co-expression with GluN2B. This avoided
complications arising from the ‘a’ isoforms that are involved with
Mg2+-induced potentiation at NMDARs16. Also, the 1–4b isoform
is expressed during early development17, which is important given
that the effects of the GluN2B mutations predominate in children6.
Receptors comprising GluN1–GluN2BC461F and GluN1–
GluN2BP553L showed reduced glutamate potency, by 71-fold
(EC50 = 511.4± 55.5 μM) and 1.7-fold (12.7± 2.0 μM), respec-
tively, compared to GluN1–GluN2B wild-type (WT, EC50 = 7.2±
0.8 μM; Fig. 2b, c; Supplementary Fig. 3a). By contrast, neither
GluN1–GluN2BN615I (9.2± 1.2 μM) nor GluN1–GluN2BV618G
(6.1± 1.4 μM) affected glutamate potency (Fig. 2d, e).
We then assessed the glutamate-activated current proﬁle for
GluN1–GluN2B receptors. No changes were apparent for
NMDARs with C461F, N615I and V618G mutations compared
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to wild-type GluN2B, but for P553, which is highly conserved
amongst iGluRs (Supplementary Fig 3b), switching to
leucine increased glutamate current desensitisation compared to
GluN1–GluN2BWT (wild-type decay τ = 21.17± 0.31 s;
GluN1–GluN2BP553L: τ = 420.3± 30.1 ms; Fig. 2c). Finally, we
compared the maximal glutamate current densities (maximal
current /cell capacitance), for all four mutants. No changes were
apparent, apart from C416F, which caused a reduction (Supple-
mentary Fig. 3c).
Ion channel mutants and Mg2+ voltage-dependent block. The
ion channel mutants N615I and V618G, were previously reported
as gain-of-function NMDAR mutations due to the loss of voltage-
dependent channel block by Mg2+ ions6. To explore the activa-
tion of NMDARs at membrane potentials where they would
normally remain blocked, we used whole-cell electrophysiology
on recombinant NMDARs expressed in HEK293 cells and
structural modelling. To probe the block,
concentration–inhibition relationships for Mg2+ (1 μM–10 mM)
were generated at −60 mV (Fig. 3a). The Mg2+ IC50 was deter-
mined for GluN1–GluN2BWT only (141.7± 40.2 μM), as
GluN1–GluN2BN615I and GluN1–GluN2BV618G were unaffected
by external Mg2+ (Fig. 3a; Supplementary Fig. 4b). Indeed,
GluN1–GluN2BV618G revealed a small increase in current at high
Mg2+ concentrations (3–10 mM).
To predict the location for the Mg2+ binding site in the
NMDAR channel and how this may be disrupted by the
mutations, we used density functional theory (DFT) (Fig. 3b, c;
Supplementary Fig 4a). DFT was selected as it is a quantum
mechanical modelling method that is more accurate than
molecular docking for predicting stable binding modes for ions
(which are small and spherical with minimal geometric
constraints that docking software normally relies upon18). This
analysis revealed that four asparagine residues (N616), donated
by each GluN1 and GluN2B subunit, are directly involved in the
coordination of Mg2+ along with two water molecules (Fig. 3b, c).
Two further asparagines (N615) from GluN2B subunits are also
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Fig. 1 Location of missense mutations in the GluN2B subunit. a Homology hybrid model of the human tetrameric GluN1–GluN2B receptor using the rat
(PDB: 4PE5) and frog (PDB: 4TLL, 4TLM) crystal structures as templates (orange: GluN1, blue: GluN2B). The amino terminal domain (ATD), ligand binding
domain (LBD) and transmembrane domain (TMD) of the subunits are shown in ribbon format with the residues selected for study in green in stick format.
b C461 is located in the S1 region of the LBD, proximal to the glutamate binding site with bound glutamate (yellow). c Glutamate at the orthosteric binding
site (position taken from rat NMDAR structure; PDB: 4PE5). d P553 is located in pre-M1 in close proximity to M3. e N615 is located at the beginning of the
M2–M3 linker and V618 is in the M2–M3 linker, its side-chain faces away from the channel pore
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likely to stabilise Mg2+ coordination by forming H-bonds with
N616 from the GluN1 subunits (Fig. 3b, c). This coordination site
for Mg2+ would explain the disruption caused by GluN2BN615I,
following the loss of H-bonding between GluN2BN615 and
GluN1N616 (Supplementary Fig. 4c).
By removing the Mg2+ block with the channel mutations, it
was conceivable that the channel permeability to Mg2+ was also
affected, especially as amino acid substitutions in the channel will
alter divalent cation selectivity19–22 and asparagines in the
M2–M3 linker are important for binding divalent cations23. To
assess Mg2+ permeability the external solution was altered such
that Mg2+ was the only current-carrying cation (Mg2+ solution).
Consistent with a lack of Mg2+ permeation in wild-type receptors,
exposing GluN1–GluN2BWT to Mg2+ solution at −60 mV did not
elicit a response to glutamate and glycine (10 μM). The same
result was apparent for GluN1–GluN2BN615I (Fig. 4a; Table 1).
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Fig. 2 Effects of GluN2B mutations on glutamate potency. a Primary sequence alignment of human NMDAR subunits showing the locations for the four
selected mutations. The mutations are shown in colour in the sequence and on the linear subunit structure (crosses) showing the ATD, CTD (C-terminal
domain), S1 and S2 regions, plus the M1-M4 TMD. b–e Glutamate concentration–response curves in the presence of 10 μM glycine and normalised to the
maximum peak response evoked by saturating glutamate. Control curves in c–e are taken from b. The glutamate EC50s and Hill slopes (n) are: b
GluN1–GluN2BWT 7.18± 0.82 μM, 1.45± 0.12; GluN2BC461F 511.40± 55.49 μM, 1.44± 0.03 unpaired Student’s t-test p< 0.0001, c GluN2BP553L 12.67±
2.01 μM, 0.89± 0.05, p< 0.05, d GluN2BN615I 9.15± 1.23μM, 1.27± 0.13, p> 0.05; and e GluN2BV618G 6.08± 1.43 μM, 1.23± 0.12, p> 0.05. Inset in c
shows glutamate-activated currents (to saturating concentration of glutamate and 10 μM glycine) in HEK293 cells expressing GluN1–GluN2BWT or
GluN1–GluN2BP553L at −30mV. The red lines show exponential curve ﬁts
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However, activating GluN1–GluN2BV618G in Mg2+-solution
resulted in large inward currents attaining 58.4± 9.8 % of the
maximum glutamate-activated current in Krebs solution in the
absence of Mg2+ (Fig. 4a; Table 1). This indicated that Mg2+
permeates the channel, possibly due to changes in pore
constriction and altered side-chain conformations in the channel
lumen resulting from the V618G substitution. To assess whether
the channel mutants affected Ca2+ permeation, we modiﬁed the
external solution to make Ca2+ the only current-carrying cation24
(Ca2+ solution). The Ca2+ current activated by 10 μM glutamate
and 10 μM glycine was comparable for GluN1–GluN2BWT and
GluN1–GluN2BV618G (Table 1) and signiﬁcantly reduced for
GluN1–GluN2BN615I, reaching only 11.07± 1.04 % of the current
activated by the agonists in normal Krebs solution. This implied a
signiﬁcant reduction in Ca2+ permeation for GluN2BN615I.
To examine how the voltage-sensitive Mg2+ block was affected
by N615I and V618G, current–voltage (I–V) relationships were
constructed in Krebs containing 1.2 mM Mg2+. For wild-type
NMDARs, the expected Mg2+ block at negative membrane
potentials was evident. However, for the mutants, the I–V
relationships lacked the negative slope conductance, adopting a
linear relationship at negative membrane potentials in accord
with a loss of Mg2+ inhibition (Fig. 4b; Table 2). These data,
coupled to the structural analysis, indicated that the loss of Mg2+
voltage-dependent block resulted from a disruption to the Mg2+
binding site in both channel mutants and from increased Mg2+
permeability in GluN1–GluN2BV618G.
Quantifying Mg2+ block using the trapping model. To quan-
titatively account for the experimental data with the channel
blocking mutants, we devised a kinetic model. A sequential open
channel block mechanism was inconsistent with the reported
characteristics of Mg2+ block because agonist EC50 and the
kinetics of whole-cell currents25 are unaffected. Also, the NMDA
channel burst length in Mg2+ does not increase linearly with
Mg2+ concentration24. We adopted the ‘trapping model’ as it
explained the broadest number of observations with regard to
Mg2+ block of the NMDA channel25–27. This model enabled
Mg2+ to become trapped in the channel after dissociation of
glutamate25,27–30. The elements of the model are:
Where KA is the glutamate dissociation constant and KE is the
gating constant, A represents glutamate (assuming saturated
glycine binding to GluN1), R is the NMDAR in shut (R, AR) or
open (AR*) or blocked (ARMg, AR*Mg) conformations bound
with Mg2+, and KMg represents the dissociation constant for
Mg2+. In a controlled heterologous expression system, each
a
b
WT
V618G
N615I
1 10 100 1000 10,000
0
20
40
60
80
100
120
G
lu
ta
m
at
e-
ac
tiv
at
ed
 c
ur
re
nt
 
(no
rm
ali
ze
d t
o c
trl 
I G
lu
,
 
%
) 
Mg2+ concentration (µM)
N616
N615
N616
N616
N616
N615
Mg2+
H2O
H2ON616
N615
N616 N616
N616
N615
V618
V618
Mg2+
GluN1 GluN2B
M2M2
M3 c
GluN1 GluN2B
H2O
H2O
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NMDAR is expected to contain two GluN1 subunits and two
GluN2B subunits. Although the subunits could interact in a
cooperative manner at several levels, we assumed for simplicity
that they behaved independently31.
The kinetic model was used in conjunction with a two-barrier
ionic permeation model32,33 (see Methods), allowing Mg2+ to
permeate the channel especially at negative membrane
potentials29,34. Using least-squares optimisation of the Mg2+
block parameters, the Mg2+ concentration–inhibition data
(Fig. 3a) and current–voltage (I–V) relationship for the wild-
type NMDAR (Fig. 4b; Supplementary Fig. 5) were ﬁtted
(Table 2). This also estimated the dissociation constant for Mg2
+ binding (3.82± 0.69 mM, at 0 mV; 123 μM at −60mV) in the
channel and its voltage dependence (δMg) (0.88± 0.04). The latter
implied (by assuming a linear electric ﬁeld across the cell
membrane) that the Mg2+ site was located ~4/5 into the channel
from the external surface.
Ion channel mutants and binding of memantine. As the
channel mutants ablated Mg2+ block, we then investigated whe-
ther the voltage-dependent blocker memantine was similarly
affected. Memantine has anticonvulsant properties in animal
models of epilepsy35. It presents a safe proﬁle in children36 with
variable effectiveness as an adjunctive therapy for gain-of-
function missense mutations in GluN2A37 and GluN2D sub-
units7. Thus, it may be therapeutically useful where Mg2+ block is
compromised.
First, we examined the primary location for memantine
binding using molecular docking. In wild-type NMDARs,
memantine binds above the central vestibule near M2 by H-
bonding to asparagine residues N615 and N616 (Fig. 5a). At this
site, memantine is orientated with its charged quaternary amine
facing towards the intracellular end of the channel. By contrast,
molecular docking with N615I revealed two deﬁned memantine
poses. One coincides with the same position deﬁned in wild-type
NMDARs, whereas the second was centred above the channel
gate to a lateral site deﬁned by a cavity between M2 and M3
(Supplementary Fig. 6b).
Whether memantine binding was affected by Mg2+ in the
channel was investigated using molecular docking with a wild-
type NMDAR. Memantine was laterally displaced from its
binding site above the channel gate by bound Mg2+ (Supple-
mentary Fig. 6c, d), consistent with partially overlapping binding
sites30. We therefore incorporated into our kinetic model the
premise that memantine and Mg2+ competed for a mutually
exclusive binding site. As with Mg2+ block, we adopted the
trapping model, especially as the deactivation rate for glutamate-
activated currents remained unaffected by memantine
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(Supplementary Fig. 6e). Lastly, there was no evidence for
memantine permeating through the channel and so this
possibility was discounted when analysing the block.
The experimental data obtained in zero Mg2+ (at −30 mV)
revealed the channel mutants either increased (GluN1–
GluN2BN615I IC50 = 1.54± 0.27 μM) or reduced (GluN1–
GluN2BV618G IC50 = 52.23± 3.67 μM) memantine potency com-
pared to GluN1–GluN2BWT (IC50 = 7.33± 1.86 μM; Fig. 5b,
Supplementary Fig. 6a). Compared to wild-type, both mutants
showed marked reductions in outward rectiﬁcation at depolarised
potentials due to the memantine block. At negative potentials, the
memantine block was comparable between all the NMDARs,
particularly at high memantine concentrations for V618G
(Fig. 5d). Interestingly, the trapping model suggested the voltage
dependence (δ) for block was signiﬁcantly reduced for the
channel mutants, interpreted as a reduced exposure of the
memantine binding site to the membrane electric ﬁeld
(GluN2BWT: δ = 0.65± 0.03; GluN2BN615I: 0.42± 0.11;
GluN2BV618G: 0.42± 0.03; p< 0.05) (Table 2).
We then used the blocking parameters estimated by the
trapping model ﬁts of the I–V relationships in memantine (in 0
and 1.2 mM Mg2+ for wild-type receptors; in 1.2 mM Mg2+ for
the mutants) to ﬁt curves to the memantine
concentration–inhibition data (Fig. 5b, c). The curve for
GluN1–GluN2BWT was shifted to the right by 1.2 mM Mg2+,
consistent with mutually exclusive binding of Mg2+ and
memantine30 (Fig. 5b). For the channel mutants, the theoretical
memantine inhibition curves in 0 and 1.2 mM Mg2+ overlapped
due to the loss of Mg2+ sensitivity. With regard to the voltage
sensitivity of memantine block, under similar conditions for wild-
type and mutant NMDARs, good agreement between the
experimental data and the model predictions was evident. This
supported the assumption that Mg2+ and memantine binding are
mutually exclusive and validated the use of the trapping model.
Indeed, these data also accord with structural predictions of partly
overlapping binding sites from the hybrid model suggesting
memantine binds just superﬁcial to Mg2+.
Effect of GluN2B mutations on neuronal NMDARs. The
impact of the GluN2B mutations was assessed on neuronal
NMDARs by evoking network-driven NMDAR-mediated EPSCs
in hippocampal neurons transfected with either wild-type or
mutant GluN2B constructs. Hippocampal cultures were super-
fused with Krebs containing 10 μM CNQX and 20 μM bicuculline
to block non-NMDA receptor and GABAA receptor-mediated
currents, respectively. By removing external Mg2+ the appearance
of spontaneous EPSCs was evident and these were blocked by the
NMDAR antagonist, APV (20 μM) (Supplementary Fig. 7). To
obtain phase-locked EPSCs, a loose cell-attached patch electrode
was used to serially stimulate presynaptic neurons yielding
evoked EPSCs in postsynaptic neurons.
The relative contributions of GluN2A and GluN2B subunits to
NMDAR-mediated currents (at 13–15 DIV) was assessed using
the selective antagonists, TCN213 (30 μM, for GluN2A) and
ifenprodil (3 μM, for GluN2B). Ifenprodil reduced the peak EPSC
amplitude and decreased the decay time by 30%, whereas 30 μM
TCN213 minimally (10 %) reduced peak EPSC amplitude but
caused a 40% prolongation of the EPSC decay (Fig. 6a). This
proﬁle reveals the faster current decay for GluN2A- compared to
GluN2B-containing NMDARs. It also reproduces the level of
ifenprodil block of glutamate currents observed for recombinant
GluN1/GluN2A/GluN2B triheteromers38, as well as the reduced
sensitivity to allosteric GluN2A antagonists by the presence of
GluN2B in the heteromer38,39. For GluN1-GluN2A diheteromers,
30 μM TCN213 is nearly equivalent to the IC5040. The partial
block by TCN213 is the expected proﬁle for triheteromeric
NMDARs and accords with previous studies at the same
developmental stages in hippocampal41 and cortical cultures40,42
and acute cortical slices43. Moreover, our transfection protocol
did not cause overexpression of the GluN2B subunit as the EPSC
peak amplitude and decay remained comparable between
untransfected and (GluN2BWT) transfected neurons (Supple-
mentary Fig. 8).
The impact of the GluN2B mutations on EPSC peak
amplitudes and decays was compared to control EPSCs recorded
from GluN2BWT transfected neurons. For GluN2BC461F,
GluN2BP553L and GluN2BN615I expressing neurons, the EPSCs
exhibited faster decay times compared to GluN2BWT counter-
parts (GluN2BWT: 767.7± 33.7 ms; GluN2BC461F: 517.3± 25.1
ms; GluN2BP553L: 522.2± 29 ms; GluN2BN615I: 585.4± 44.9 ms;
Fig. 6c–g). In addition, GluN2BP553L also reduced the mean peak
EPSC amplitude (GluN2BWT: −359.5± 39.7 pA; GluN2BP553L:
−206.3± 36.4 pA), possibly reﬂecting the rapidly desensitising
nature of this mutant NMDAR (Fig. 6b). By contrast, the channel
mutant GluN2BV618G did not affect the proﬁle of NMDAR-
mediated EPSCs (GluN2BV618G peak −341.2± 40.4 pA; decay
706.4± 31.8 ms; Fig. 6b, c, h).
We next examined the effect of external Mg2+ block on EPSCs
(at −70mV) from neurons expressing GluN2BWT, GluN2BN615I
or GluN2BV618G subunits (Fig. 7a–f). The mean peak amplitude
and charge transfer (area) for evoked EPSCs were compared
between 0 and 1.2 mM external Mg2+ conditions (Fig. 7g, h).
EPSC amplitudes and areas for neurons expressing wild-type
constructs were inhibited by Mg2+ (GluN2BWT: 88.8± 2.8 %),
and this was notably reduced for the mutant constructs
GluN2BN615I (73.8± 4.7%) and GluN2BV618G (68.7± 8.9 %;
Fig. 7g, h).
To examine whether memantine could be an effective
therapeutic agent by blocking gain-of-function mutant NMDARs,
we determined the level of inhibition for EPSCs in 0 Mg2+
(Fig. 8a–f), chosen as 1.2 mM Mg2+ alone would cause
substantive inhibition preventing quantiﬁcation of the meman-
tine block. Under these conditions, peak EPSC amplitude and
Table 1 Ion permeation of wild-type and mutant GluN2B-containing NMDARs
Mg2+ solution Ca2+ solution
Construct IMg current density (pA/pF) IMg/IKrebs (%) ICa current density (pA/pF) ICa/IKrebs (%)
WT −0.07± 0.03 0.91± 0.37 −7.08± 2.12 52.83± 1.07
N615I −0.09± 0.03 1.63± 0.64 −0.47± 0.10** 11.07± 1.04**
V618G −10.28± 2.53** 58.46± 9.8** −5.00± 0.64 46.28± 3.18
Table reports membrane current densities after NMDAR activation by 10 μM glutamate and 10 μM glycine co-applied to HEK293 cells voltage clamped at −60mV in either external Mg2+ solution (100
mM) or Ca2+ solution (100mM). Current densities are also reported as a percentage of current in Mg2+ and Ca2+ solution with regard to current measured in normal Krebs solution. Different sets of
cells were used for Mg2+ solution and Ca2+ solution. Number of cells for each condition= 5–8. One-way ANOVA with Dunnett’s post-hoc test was performed to assess the changes in the ion
permeability between wild-type and mutant receptors
**p< 0.01
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charge transfer (area) for evoked NMDAR-mediated EPSCs were
inhibited to a comparable extent by memantine for GluN2BWT,
GluN2BN615I and GluN2BV618G transfected neurons (Fig. 8g, h),
which was also comparable to the degree of block of recombinant
NMDARs receptors at −70mV (Fig. 5c, d).
Discussion
Dysfunctional excitatory synaptic transmission, caused by
NMDAR mutations, has been implicated in numerous neurode-
velopmental disorders5,6,8,9. Here, we investigated missense
mutations in the human GluN2B subunit that associate with
Lennox Gastaut syndrome with autistic features, intellectual dis-
ability and West syndrome in children. The expression proﬁle of
GluN2B is highest in the developing nervous system where it
partly underpins synaptic plasticity and normal brain
function1,44. The aim of this study was to understand the
mechanisms underlying NMDAR dysfunction and consider
potential pharmacotherapies targeting NMDARs. Our structural
and functional studies suggest that pathogenicity arising from
GluN2B variants is likely to be a consequence of compromised
NMDAR physiology. However, some GluN2B variants are not
associated with signiﬁcant functional defects, which highlight the
importance of structure–function studies in conﬁrming likely
pathogenicity. We chose four GluN2B mutations for detailed
study in recombinant systems as diheteromers, before investi-
gating their effects in neurons as diheteromers and triheteromers
with native subunits to mimic the heterozygous expression proﬁle
likely to occur in patients carrying the mutations.
We located C461 to S1 of the LBD, where it is not directly
involved in binding glutamate, but nevertheless, glutamate
potency was reduced by C461F. Our NMDAR model suggested
that new van-der-Waals interactions could form between F461
and neighbouring hydrophobic residues, V417, L465 and F529.
These may stabilise a conformation of S1 that could hinder glu-
tamate access to its binding site, and/or affect the ‘clam-shell
ligand-locking’ operation of the LBD, which occurs after gluta-
mate is bound13,45. In neurons, C461F increased the decay rate of
NMDAR-mediated EPSCs, which may reﬂect faster glutamate
unbinding, accounting for the lower glutamate potency for
receptors containing GluN2BC461F46. Furthermore, the pheno-
typic effect of C461F will be offset in neurons by native
NMDARs. In the presence of wild-type GluN2 isoforms,
NMDARs will likely contain 0, 1 or 2 copies of a mutant GluN2B
subunit. In such triheteromers, we would expect a reduced glu-
tamate potency shift46 that would also mitigate any effects of the
mutation on the EPSC proﬁle, possibly explaining the unaffected
peak EPSC amplitude possibly due to synaptic glutamate con-
centrations (1–2 mM)47 that could saturate lower afﬁnity
GluN2BC461F-containing receptors. However, faster EPSC decay
rates will lower charge transfer, reducing excitation and imposing
stringent time constraints on coincidence detection that could
compromise synaptic plasticity. Overall, we deﬁne C461F that is
associated with Lennox Gastaut syndrome with autistic features,
as a loss-of-function NMDAR mutation. This is consistent with
reduced glutamatergic neurotransmission in animal models of
autism-spectrum disorder (e.g. BTBR mice)48 where the pheno-
type can be improved by a selective AMPAR positive allosteric
Table 2 Trapping block model parameters
Blockers Model values WT N615I V618G
KA (μM) 8 8 8
KE 8 8 8
HE (mV) 650 650 650
Mg2+ KMg (0mV) (mM) 1.07± 0.19 — —
IC50 (−60mV) (μM) 142± 40 — —
δMg 0.88± 0.04 — —
Memantine KMem (0mV) (μM) 10.34± 0.702 1.53± 0.42 86.5± 7.03
IC50 (−30mV) (μM) 7.33± 1.86 1.54± 0.27 52.2± 3.67
δMem 0.65± 0.026 0.42± 0.11 0.42± 0.03
Vo (mV) 39.1 59.9 59.8
The table reports values for dissociation and conformational constants used in the trapping receptor model where A is glutamate (assuming saturated glycine binding to GluN1), R is the NMDAR in shut
(R, AR) or open (AR*) forms, bound with Mg2+ or memantine (Mem) in shut (RMem, ARMem, RMg, ARMg) or blocked (AR*Mem, AR*Mg) forms. KA, KMem and KMg represent the dissociation
constants for glutamate, Mg2+ and memantine, respectively. KE is a conformational constant for channel activation. HE indicates the intrinsic voltage-dependent gating of GluN1–GluN2B receptors. IC50
represents the concentration of either Mg2+ or memantine causing a 50% reduction in the glutamate-activated current measured at −30mV for memantine and at −60mV for Mg2+. V0 is the change in
membrane potential (Vm) that results in an e-fold change in the antagonist dissociation constant, where V0 = RT/δzF, and δ represents the fraction of membrane potential sensed by the blocker (δMem for
memantine, and δMg for Mg2+) when it is bound in the channel; z is the charge of the blocker, and R, T and F are the gas constant, absolute temperature and the Faraday constant, respectively.
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modulator (AMPAKINE)48. Lennox Gastaut syndrome is a severe
form of childhood epilepsy. High expression of mutant GluN2B
subunits during early development could also compromise
neurotransmitter-based signalling (e.g. GABA release via pre-
synaptic NMDARs49) as well as the operation of distinct cell types
(interneurons/principal neurons)50 with consequences for exci-
tation and inhibition.
By comparison, P553 is found in pre-M1 and minimally
affected glutamate potency, but notably, the rate of desensitisation
of GluN1–GluN2BP553L was markedly increased. Pre-M1 is
highly conserved amongst iGluRs (Supplementary Fig. 3b) with
four key residues (F550 (pre-M1), P553 (pre-M1), W559 (M1)
and Y646 (M3), human GluN2B numbering) forming a
hydrophobic box, which inﬂuences desensitisation14. Exchanging
a single residue in this region (F/Y554 in NMDARs for L in
AMPARs) transfers, to some extent, the desensitising proﬁle of
AMPARs to NMDARs14.
Pre-M1 is also in close proximity to the highly conserved
transduction element, -SYTANLAAF-, in M3 of GluN2B. This
motif is involved in coupling ligand binding to channel opening,
and controlling open channel probability15. Thus, forming new
interactions between L553 and N649 and/or L650 in the motif
(Supplementary Fig. 2b) would likely interfere with gating.
Indeed, substituting this residue in GluN2A either slowed (Glu-
N2AP552R) or accelerated (GluN2AP552G) glutamate current
decay8.
N615
N615
N616
N616
MEM
N616N616
GluN2BGluN1
GluN2BWT
400pA
3s
0 1 3 10 100a b
0.01 0.1 1 10 100
0
20
40
60
80
100
G
lu
ta
m
at
e-
ac
tiv
a
te
d 
cu
rre
n
t
(no
rm
ali
ze
d t
o c
trl
 I G
lu
,
 
%
)
Memantine (µM)
WT
V618G
N615I
WT + Mg calc
0 Mg2+
1.2 mM Mg2+
1.2 mM Mg2+
1.2 mM Mg2+
c
WT +30µM Mem
N615I +30µM
WT  (+ 30µM Mem)
V618G (+ 300µM)
V618G (+ 30µM)WT +30µM Mem
WT +30µM Mem
–100 –50
0 50 100
–1000
1000
2000
3000
4000
5000
I (p
A)
V (mV)
–100 –50
0 50 100
–1000
1000
2000
3000
4000
5000
I (p
A)
V (mV)
–100 –50
0 50 100
–1000
1000
2000
3000
4000
5000
I (p
A)
V (mV)
–100 –50
0 50 100
–1000
1000
2000
3000
4000
5000
I (p
A)
V (mV)
d
Fig. 5Memantine inhibition of GluN1–GluN2B NMDARs. aMolecular docking of memantine in the channel at the trapping site. Note memantine binds just
above the channel gate with the quaternary amine facing towards the channel pore and H-bonding (dashed lines) with the two N616 residues in GluN1
(red). H-bonding between GluN2BN615 and GluN1N616 (pink arrowhead) is also proposed to stabilise memantine coordination. b Upper panel, memantine
inhibition of 10 μM glutamate-activated currents at –30mV in a HEK293 cell expressing GluN1–GluN2BWT. Glutamate-activated currents in increasing
concentrations of memantine are normalised to control currents elicited by 10 μM glutamate and 10 μM glycine. Lower panel, memantine
concentration–inhibition relationships for WT and GluN2BN615I and GluN2BV618G mutants. The curve ﬁts were generated using the trapping model (black
line: WT, red: N615I, blue: V618G). Dashed line shows the calculated memantine concentration–inhibition curve (WT +Mg calc) in the presence of 1.2 mM
Mg2+ for WT receptors. Currents are normalised to the control current activated by 10 μM glutamate and 10 μM glycine (=100%). The experimental IC50s
are: GluN2BWT: 7.33± 1.86 μM, n= 6; GluN2BN615I: 1.54± 0.27 μM, n= 5, p< 0.001; GluN2BV618G: 52.23± 3.67 μM, n= 11, p< 0.001) one-way ANOVA
with Dunnett’s post-hoc test. The predicted IC50s from the trapping model are (μM): GluN2BWT 5.48 μM; GluN2BN615I 0.89 μM; GluN2BV618G 52.6 μM;
and GluN2BWT in the presence of 1.2 mM Mg2+o 18.6 μM. c, d I–V relationships for currents activated by 10 μM glutamate and 10 μM glycine in the
absence (0mM) and presence (1.2 mM) of Mg2+, with 30 or 300 μM memantine for WT and GluN2B channel mutants. The curves are generated using
the trapping block model (black: WT, red: N615I; blue: V618G)
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Consistent with a desensitising phenotype, expressing
GluN2BP553L in neurons increased the decay rate and reduced
peak amplitudes for NMDAR-mediated EPSCs. A reduction in
surface trafﬁcking of GluN2BP553L has been reported8. This was
not evident in our study and may reﬂect distinct trafﬁcking
itineraries for different GluN1 isoforms (GluN1–4b used here vs
GluN1–1a in ref. 8). As such, P553L is a loss-of-function muta-
tion associated with severe ID. The profound effects of P553L on
excitatory synaptic transmission might explain the clinical phe-
notype, especially given the roles NMDARs have in higher cog-
nitive function.
For recombinant NMDARs containing the channel mutants
N615I or V618G, voltage-dependent Mg2+ block was lost. This
unique feature underlies the property of coincidence detection,
requiring coordinated agonist binding (presynaptic release) with
membrane depolarisation (postsynaptic activity) for NMDAR
activation1. Despite their close physical location, we discovered
distinct mechanistic effects for these two mutations, providing
new insight into NMDAR channel structure and function.
GluN2BN615 stabilises the Mg2+ coordination site by H-
bonding to N616 in GluN1, which with N616 from GluN2B,
directly coordinates Mg2+. Our results are consistent with recent
ﬁndings of Mesbahi-Vasey et al.23 They utilised MD simulations
and on comparison with our DFT approach, both studies iden-
tiﬁed 6 asparagines as participating in the Mg2+ binding site.
Furthermore, Mesbahi-Vasey suggested that only four asparagine
residues would directly coordinate Mg2+. Our present results
agree, and we further propose that the four asparagine residues
are those at position 616 (in GluN1 and GluN2B subunits),
whereas those at position 615 (in GluN2B) indirectly stabilise
Mg2+ coordination. Disrupting the Mg2+ binding site with N615I
prevented Mg2+ block without causing Mg2+ permeability.
However, V618G not only removed the block but also permitted
Mg2+ permeation via the channel. The pore architecture is highly
conserved across iGluRs. It is characterised by a narrow
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constriction at the extracellular end that forms the selectivity ﬁlter
deﬁned by a ring of six asparagine in the M2–M3 linker in
NMDARs. Substitutions of N616 (in GluN1 and GluN2) both
affected Ca2+ permeability20. In our study, we ﬁnd that
GluN2BN615 is also important for Ca2+ binding, evident by the
reduced current for GluN1–GluN2BN615I when Ca2+ is the only
current-carrying ion.
The channel lining contains hydrophobic residues with their
side-chains rotated away from the lumen forming a ‘cuff’ that
selects for divalent cation permeability (e.g. W607L in M2 of
GluN2B)22. Valine 618 is ideally placed in the M2–M3 linker of
GluN2B to interact with neighbouring hydrophobic residues in
M2, M3 and in the M2–M3 linker. If, as proposed, outward
movement in M3 promotes channel widening after receptor
activation51, GluN2BV618 could have a role in such a mechanism.
Thus when mutated, Mg2+ permeation increases, resulting from
faster Mg2+ unbinding in the channel. This could be interpreted
as a reduction in the energy barriers for ion permeation, com-
promising the Mg2+ coordination site.
The channel mutations N615I and V618G may be classed as
gain-of-function mutations, potentially underlying the increased
excitability in West syndrome for which the onset6 associates
with the high expression proﬁle of GluN2B in late infancy
(<1year)52. For V618G, increased susceptibility to excitotoxicity
is likely given the lack of Mg2+ block combined with comparable
levels of Ca2+ permeation compared to wild-type NMDARs.
However, the reduced Ca2+ permeation noted with N615I may
compromise synapse formation, maturation and synaptic
plasticity.
In principle, the lack of Mg2+ block could be compensated by
another voltage-sensitive channel blocker such as memantine.
However, memantine was more potent at GluN1–GluN2BN615I
and less potent at GluN1–GluN2BV618G (cf. ref. 53), compared to
wild-type receptors, with implications for therapeutics. Moreover,
the memantine binding site was likely displaced by the channel
mutations (δMem was reduced by ~30% compared to wild-type
NMDARs) reducing voltage sensitivity compared to wild-type.
Memantine binding was also affected by the presence of bound
Mg2+ in the channel (for wild-type but not of course for the
channel mutants), which reduced memantine potency suggesting
overlapping binding sites. The trapping model was able to
account for the mechanism of action for memantine by reduced
binding to GluN1–GluN2BV618G and increased binding at
GluN1–GluN2BN615I, both of which are coupled to reduced
voltage sensitivity. This suggested a re-positioning of the mem-
antine binding site in the membrane electric ﬁeld, with a reduced
voltage dependency in accord with displacement of the structu-
rally predicted site away from the channel pore (pose 2, Sup-
plementary Fig. 6b).
Our kinetic and molecular docking results are consistent with
overlapping sites for Mg2+ and memantine26,30,54, with Mg2+
binding at the level of the asparagine residues, whereas meman-
tine binds just above the channel pore. The memantine site agrees
with the cryo-EM structure for a triheteromeric NMDAR
(GluN1/GluN2A/GluN2B) bound with another trapping channel
blocker, MK-801, which binds in the same channel vestibule as
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Fig. 8 Memantine inhibition of NMDAR-mediated EPSCs. Synaptic currents
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μM for GluN2BWT and GluN2BN615I; and 300 μM for GluN2BV618G) in
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memantine with its positively charged amino group also facing
the channel pore55. However, for memantine, we found two
distinct positions for binding to GluN1–GluN2BN615I. One
coincided with the binding site observed for the wild-type
receptor, whereas the second position implied displacement of the
site to a cavity in the vestibule between M2 and M3.
The effect of the channel mutants on memantine inhibition
may also relate to the ‘two-sites hypothesis’ for memantine
binding involving a high afﬁnity (trapping) site and a second low
afﬁnity (non-trapping) site, sometimes referred to as the ‘super-
ﬁcial site’26. These two sites were proposed to distinguish between
different mechanisms of action for memantine and other
NMDAR channel blockers26. This hypothesis also relates to the
voltage dependency of the two sites. Blanpied et al.28 described a
primary channel site for memantine with a V0 = 31.5 mV and a
second site with V0 = 67.2 mV (V0 is the change in membrane
potential causing an e-fold change in the dissociation constant,
KMem). Interestingly, we ﬁnd comparable values for GluN2BWT
(V0 = 39.1 mV) and mutant receptors (GluN2BN615I V0 = 59.9
mV and GluN2BV618G V0 = 59.8 mV; Table 2). This suggests
higher occupancy of the primary (trapping) site in wild-type
NMDARs, compared to greater occupancy of the non-trapping,
superﬁcial site in the mutants. Despite the similar V0 for the
superﬁcial site, our data show that memantine does not prevent
channel gating (evident by the unaffected EPSC decay with the
blocker) (Supplementary Fig 6e), which is a central premise of the
trapping block mechanism25. Thus, the change in V0 would
suggest either the binding site is displaced or the membrane
electric ﬁeld is perturbed following the channel mutations. Other
mechanisms might also underlie the different modes of action for
fully (e.g. ketamine) and partial-trapping (e.g. memantine)
blockers such as the conformational state and receptor subunit
composition56,57.
Given the predominant early expression of GluN2B, a role in
synaptogenesis and cognitive function is likely to be pre-
eminent44. The clinical phenotypes of individuals with GluN2B
mutations are likely to correlate with the nature of NMDAR
dysfunction, and with the impact this has on the NMDAR sub-
unit switch during development, with consequences for excitatory
synapse formation3.
Of the four mutations studied in detail, two present as loss-of-
function (C461F and P553L), and the other two as gain-of-
function (N615I, V618G). On this basis, memantine cannot be
considered an all-encompassing treatment for NMDAR muta-
tions and will be therapeutically beneﬁcial only for selected gain-
of-function channel mutants. The inhibition of NMDAR-
mediated EPSCs at negative membrane potentials by meman-
tine was comparable between wild-type and N615I or V618G-
expressing neurons supporting a role for this drug as a potential
therapy to mimic lost Mg2+ block at these potentials in neurons.
Interestingly, at depolarised potentials, memantine was more
efﬁcacious in the channel mutants compared to wild-type
NMDARs, which might be advantageous during seizures invol-
ving depolarising membrane potential shifts.
Methods
Bioinformatics analysis. Missense mutations in GRIN2B that associate with dis-
ease, were assessed for pathogenicity using several predictive bioinformatic tools:
SIFT (http://sift.jcvi.org), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and
Mutation Taster (http://www.mutationtaster.org). The 1000 Genome Project
database (http://www.1000genomes.org) was also utilised to distinguish disease-
causing mutations from common benign polymorphisms. Thus selected missense
mutations thought to be disease-causing were predicted by SIFT, Polyphen-2 and
Mutation Taster, and were absent from the 1000 Genomes database.
Structure modelling and molecular docking. A near-complete structure of the
human NMDAR was generated using MODELLER 9.1058 based on crystal
structure templates of rat (PDB 4PE5) and Xenopus (PDB 4TLL, 4TLM)
GluN1–GluN2B receptors. These species exhibit 99 and 90% identity, respectively,
with the human GluN1–GluN2B receptor. We compiled this structure because no
human equivalent NMDAR structure exists and also we needed to inﬁll those
sections of the rat and Xenopus NMDAR crystal structures that have been trun-
cated or deleted as necessary pre-requisites for successful receptor crystallisation.
First, a multiple alignment of the subunits primary sequences was generated
incorporating different domains from each crystal structure, e.g. the amino term-
inal domain (ATD) (from PDB 4PE5), the ligand binding domain (LBD) (from
PDB 4PE5, 4TLL, 4TLM), and the transmembrane domains (from 4TLL and
4TLM10,11). These three crystal structures were used because each contributed high
resolution, but different, structures of the NMDAR, e.g. the Xenopus structures had
near intact channel pores, whereas the rat structure exhibited a higher sequence
identity to the human NMDAR.
GluN1 (isoform ‘a’ here to reproduce what was used in the X-ray structures)
and GluN2B subunits were ﬁrst compiled as structures in isolation, with 100
models generated and then ranked according to their discrete optimised protein
energy (DOPE) scores59. The most energy-favourable models for each subunit were
selected for co-assembling GluN1 and GluN2B, initially as a dimer by utilising
UCSF Chimera v1.9, before ﬁnal co-assembly of the NMDAR tetramer by initial
superimposition onto the rat NMDAR crystal structure. The tetrameric model of
the human NMDAR was then optimised, using MODELLER 9.10, generating 100
tetrameric models that were ranked, ﬁrstly, according to their DOPE scores and
secondly by using QMEANBrane, a quality estimation method for membrane
proteins60 that assesses the best ranks for those regions of the NMDAR that lay
within the cell membrane. These regions of the NMDAR were previously identiﬁed
using the PPM server61. The most energy-favourable model that emerged, and was
used in this study, was ﬁnally assessed by ranking according to the ‘Borda score’62.
For this score, each model ﬁt (i) within a group of N ﬁts is ranked (r) according to a
list of S different parameter scores, where S> 1. The Borda score is deﬁned by,
B ¼
XS
i¼1
ðN  rÞ:
Thus, our ranking criteria used both DOPE and QMEANBrane scores, whereby
the highest ranked models were raised in the list by the number of models ranked
beneath them.
For the docking studies with memantine (PubChem, CID:3833001) in the
NMDAR channel, we selected the quaternary amine charged structure, as the
memantine pKa is 10.7 (DrugBank ver 5) indicating that this strong base is mostly
charged (99.95 %) at physiological pH. The memantine cation was docked into a
binding cavity. This was considered to be the ‘primary (trapping) binding site’,
which we deﬁned with up to 6 asparagine residues from the M2–M3 linkers of both
GluN subunits (GluN1N616, GluN2BN615 and GluN2BN616; Supplementary Fig. 4a)
having previously been proposed to have key roles in memantine binding26,30,54,
and by the provision of two water molecules.
To deﬁne the volume of the binding site for the docking study, a centroid was
deﬁned by including all residues located within a radius of 12 Å; from the key
asparagine residues. Docking used Hermes v1.6.2 and GOLD v5.2.2. The genetic
algorithm values were set to automatically optimise the docked ligand, which was
allowed full ﬂexibility. Fifty diverse docking solutions were generated using the
CHEMPLP scoring function using the default parameters. The memantine cation
was also docked into the structural model after the two N615 residues of the
GluN2B were mutated to isoleucines (N615I). The new isoleucine rotamers were
presented in orientations that had the lowest clash scores with each other and with
the surrounding NMDAR residues (using UCSF Chimera ver 9.1).
To determine the optimal coordination of Mg2+ in its NMDAR channel
blocking position, the six asparagines (two GluN1N616, and two GluN2BN615 and
GluN2BN616) considered to interact with Mg2+19,21,22,63, were cropped from the
PDB structure. A single Mg2+ ion was then placed at the core of a centroid
determined by the six asparagines and a DFT-based geometry optimisation was
performed that also included additional water molecules to ﬁnd the lowest energy
coordination for Mg2+. The asparagine Cα atoms were also substituted for ﬁxed
atom methyl groups during the geometric optimisation to ensure that their
position did not move from their original conformation in the hybrid model and to
maintain plausible bond angles and dihedral angles between the side-chain and
backbone. DFT calculations were performed on the asparagine–Mg2+ complex,
using the Gaussian 09 package18. All calculations were performed using the hybrid
functional ωB97X-D64 with a Pople triple-zeta basis set with polarisation
(6–311G**) and the conductor-like polarisable continuum model (CPCM) to
account for solvation65. Frequency analysis was used to conﬁrm energy minima by
geometric optimisation (Supplementary Note 1).
cDNA site-directed mutagenesis and cell culture. Site-directed mutagenesis
using the QuikChange Lightning kit (Stratagene, Agilent Technologies) was used to
generate GluN2B mutants, which were conﬁrmed by Sanger DNA sequencing. All
human NMDAR GluN1 (isoforms GluN1–4b66) and GluN2B constructs were
cloned into the pRK5 expression vector (CMV promoter) with optimised Kozak
sequences.
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Human embryonic kidney cells (HEK293) were cultured with Dulbecco’s
modiﬁed Eagle medium (DMEM) with 10% v/v foetal calf serum (FCS), 2 mM
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, incubated at 37 °C in
95% air and 5% CO2. Cells were plated on poly-L-lysine coated 22 mm coverslips in
culture medium containing 400 µM D-APV for 48 h prior to electrophysiology.
GluN2B was co-transfected with GluN1 and enhanced green ﬂuorescent protein
(pEGFP-C1) in a 1:1:1 ratio using a calcium phosphate protocol: 340 mM CaCl2
and HEPES buffered saline (50 mM HEPES, 280 mM NaCl, 2.8 mM Na2PO4 and
pH 7.2).
Dissected hippocampi were dissociated from E18 Sprague Dawley rat embryos
using procedures and protocols that have been approved by the UK Home Ofﬁce.
They were dissociated into single cells using 0.1% w/v trypsin and serially triturated
with ﬂame-polished Pasteur pipettes. Cells were plated on 22 mm glass coverslips
coated with 500 μg/ml poly-D-ornithine, in minimum essential media (MEM;
Invitrogen) supplemented with 5% v/v FCS, 5% v/v HS, 10 U/ml penicillin-G, 10
μg/ml streptomycin, 2 mM L-glutamine and 20 mM glucose (plating media). After
2 h, this plating media was replaced with maintenance media composed of
Neurobasal-A (Invitrogen) supplemented with 1% v/v B-27 (Gibco), 50 U/ml
penicillin-G, 50 μg/ml streptomycin, 0.5% v/v Glutamax (Invitrogen) and 35 mM
glucose. Neurons were transfected after 10 days in vitro (DIV) with either cDNAs
for the GluN2B WT or mutants together with DsRed using Effectene (Qiagen) and
recorded at 13–15 DIV.
Electrophysiology. Whole-cell currents (in HEK293 cells) and evoked NMDAR-
mediated EPSCs (in cultured neurons) were recorded using an AxoPatch 200B
ampliﬁer (Molecular Devices, Sunnyvale, CA, USA). The external solution (Krebs)
was composed of (mM): 140 NaCl, 4.7 KCl, 2.52 CaCl2, 11 Glucose and 5 HEPES,
adjusted to pH 7.4 with NaOH. Patch pipettes (3–4 MΩ) were ﬁlled with an
internal solution containing either (mM): 120 KCl, 1 MgCl2, 11 EGTA, 10 HEPES,
1 CaCl2 and 2 K2ATP adjusted to pH 7.2 with 1M NaOH (for HEK cells); or
(mM): 145 Cs methanesulfonate, 5 MgATP, 10 BAPTA, 0.2 NaGTP, 10 HEPES, 2
QX314, adjusted to pH 7.2 with 1 M CsOH (for neurons). Currents were digitised
at 10 kHz using a Digidata 1320A (Molecular Devices, Sunnyvale, CA, USA). In
experiments using Mg2+ as the main external cation, the external solution was
replaced by a Mg2+-solution containing (mM): 100 MgCl2, 5 HEPES adjusted to
pH 7.4 with Mg(OH)2. The experiments using Ca2+ as the main external ion were
performed using a ‘Ca2+-solution’ containing (mM): 100 CaCl2, 5 HEPES adjusted
to pH 7.4 with Ca(OH)2. Glutamate (10 µM) activated currents in both Mg2+ and
Ca2+ solutions were evoked in the presence of 10 µM glycine. Cells were voltage
clamped at −60 mV. Free Mg2+ and Ca2+ concentrations in external and intra-
cellular solutions were estimated using an activity coefﬁcient of 0.56 and allowing
Mg2+ buffering by intracellular ATP and Ca2+ buffering by EGTA.
For HEK cells, glutamate-activated currents (at −30 mV) were recorded in the
presence of 10 µM glycine. For Mg2+ (at −60 mV) and memantine (at −30 mV)
concentration–inhibition relationships, different concentrations of each antagonist
were co-applied with 10 µM glutamate and 10 µM glycine using a U-tube
application system.
To examine voltage-dependent block of NMDARs, HEK293 cells were voltage
clamped at −30 mV, and currents recorded following a voltage (10 mV) step
protocol from −90 to +90 mV. The protocol was performed ﬁrst in Krebs to
measure membrane leak currents, and then repeated during the steady-state
current induced by 10 μM glutamate and 10 μM glycine with 1.2 mM Mg2+ (leak
current in Mg2+). The current induced by the agonists was determined by
subtracting the leak current before plotting the I–V relationship. Similar
procedures were followed for I–Vs determined in the presence of memantine, with
or without external Mg2+.
For hippocampal neuron experiments, the same external recording solution
described for HEK cells was used supplemented with: CNQX (10 μM), bicuculline
(20 μM) and D-serine (10 μM), to isolate the NMDAR component of EPSCs, to
block GABAA receptor-mediated inhibitory transmission, and to prevent inhibition
of NMDARs by CNQX saturating the glycine site, respectively.
NMDAR-mediated EPSCs were evoked by direct stimulation of single
neighbouring neurons using a loose cell-attached patch electrode ﬁlled with Krebs
and containing a bipolar stimulating electrode. Untransfected neighbouring
neurons were stimulated by a brief 1 ms current step (300 μA) every 12 s, whereas
EPSCs were recorded from transfected neurons voltage clamped at −70 mV. For
the pharmacological characterisation of NMDAR-mediated EPSCs, the selective
antagonists ifenprodil (+)-hemitartrate (Santacruz biotechnology) and TCN213
(Tocris) were used. If DMSO was used as a solvent the highest concentration was
0.1% v/v and this had no effect on NMDAR-mediated currents.
Analysis of membrane currents. Glutamate concentration–response relationships
were constructed by normalising glutamate-activated currents to the response
evoked by a saturating glutamate concentration. The normalised
concentration–response curves were ﬁtted with the Hill equation:
I=Imax ¼ An= An þ ECn50
  
; ð1Þ
Where Imax is the maximum response elicited by saturating glutamate
concentrations, EC50 is the concentration of glutamate resulting in half-maximal
currents, and n is the Hill coefﬁcient.
To determine Mg2+ and memantine potency peak glutamate-activated currents
were measured in the absence and presence of different antagonist concentrations
(B). Currents were normalised to the control glutamate response (10 µM glutamate
with 10 µM glycine) and the antagonist concentration causing 50% inhibition
(IC50) was determined by curve ﬁtting using the following inhibition model
equation:
y ¼ 100 ´ 1 Bn= Bn þ ICn50
   
: ð2Þ
EPSCs were analysed ofﬂine using WinWCP (Strathclyde Electrophysiology
Software, UK). Peak EPSC amplitude, the area of the EPSC (charge transfer) and
EPSC decays were measured. The decay time constants (τ) were determined by
ﬁtting the EPSC decays with a double exponential function. The weighted time
constant (τw) was calculated using the following equation, where A indicates the
relative area of each time constant.
τw ¼ ððA1:τ1Þ þ ðA2:τ2ÞÞ= A1 þ A2ð Þ: ð3Þ
Kinetic model of the NMDAR. To explain the block of the NMDAR we adopted a
trapping based model (Table 2) whereby the antagonist can remain bound to its
site (e.g. in the channel) after agonist dissociation. The membrane current (Im) was
modelled as:
Im ¼ N Vh  Vrevð Þ γPopen;
where N is the number of receptors in the cell membrane, Vh and Vrev are the
holding potential and NMDA current reversal potential, respectively, γ is the single
channel conductance and Popen is described by:
Popen Vmð Þ
¼ 1
1þ KE Vmð Þ 1þ KAGlut½ 
 n o
: 1þ Mg
2þ½ okþbo Vmð Þð Þþ Mg2þ½ ikþbi Vmð Þð Þ
kbo Vmð Þþkbi Vmð Þ þ
½Mem
KMemðVmÞ
 
ð4Þ
The weak voltage sensitivity of GluN2B receptor activation67 was accounted for
by deﬁning KE Vmð Þ ¼ KE 0mVð Þ  exp Vm=HEð Þ; where HE is the change in
membrane potential giving an e-fold change in KE and was estimated from the
control I–V relationship as 650 mV. The voltage dependence of the dissociation
constant, KMem, for memantine block was described by:
KMem Vmð Þ ¼ KMemð0mVÞ  expðδMemzMem  FVm=RTÞ
where δMem is the fraction of the membrane voltage that memantine experiences at
its binding site, zMem is the charge on memantine (=1) and F, R and T are the
Faraday constant, gas constant and the absolute temperature (K). The rate
constants (k) for binding (+) and unbinding (−) of Mg2+ ions from the outside (o)
and inside (i) of the membrane were described by:
kþbo Vmð Þ ¼ kþboð0mVÞ  exp ðδMg=2Þ  zMg  FVm=RTð Þ
  ð5Þ
kbo Vmð Þ ¼ kbo 0mVð Þ  exp ðδMg=2Þ  zMg  FVm=RTð Þ
  ð6Þ
kþbi Vmð Þ ¼ kþbi 0mVð Þ  exp ð1 δMg=2Þ  zMg  FVm=RTð Þ
  ð7Þ
kbi Vmð Þ ¼ kbi 0mVð Þ  exp ð1 δMg=2Þ  zMg  FVm=RTð Þ
  ð8Þ
where δMg is the fraction of the membrane voltage that Mg2+ experiences at its
binding site, and zMg = 2. The dissociation constant for Mg2+ block from the
outside of the membrane (KMg) was deﬁned by (k−bo + k−bi)/k+bo.
For simplicity, we based our trapping block model (Table 2) on the binding of a
single glutamate molecule causing receptor activation (assuming the glycine site
was saturated), because in this model, the block is not agonist-dependent. We also
omitted desensitised states of the receptor. The glutamate, Mg2+ and memantine
dissociation constants are shown in Table 2 along with the corresponding
conformational constant, KE for channel opening.
The initial parameter values selected were chosen to provide NMDAR Popen
values comparable with previous studies68,69, as the ion channel mutants (N615I,
V618G) have been found not to affect glutamate potency and presented
comparable deactivation rates to the wild-type GluN2B. The dissociation and
conformation constants for glutamate were ﬁxed at, KA = KE = 8, in accord with
these studies. This value was also used for KA and KE for antagonist bound receptor
states, as memantine or Mg2+ do not affect agonist potency25. The intrinsic
voltage-dependent gating of GluN1–GluN2B receptors67 was determined from the
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-02927-4 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:957 |DOI: 10.1038/s41467-018-02927-4 |www.nature.com/naturecommunications 13
I–V relationships constructed in nominally zero external Mg2+ (0 Mg2+) in the
presence of 10 μM glutamate and 10 μM glycine for the wild-type GluN1–GluN2B
receptor.
The reversal potential for glutamate (Vrev), and the number of receptors, N,
were empirically estimated for each data set. The relative position of the binding
site for memantine (δMem) and for Mg2+ (δMg) in the membrane electric ﬁeld, and
KMem (for memantine) and k−bo (for Mg2+), were all estimated by non-linear least-
squares ﬁtting of Eq. 4 to the I–V relationships. For each data set, the I–V
relationships for glutamate (control) and with memantine and Mg2+ were
simultaneously ﬁt to yield a single estimate of each parameter for the wild-type, the
N615I and V618G mutant receptors. The values of k+bo(0 mV) and k+bi(0 mV)
were ﬁxed at 5 × 107 M-1 s-1. The values for k−bi and δMg are highly correlated when
they are estimated from ﬁtting the I–V relationship in the presence of Mg2+. Given
that at the Mg2+ reversal potential the net rate of movement of Mg2+ ions through
the channel is zero, k−bi was estimated from the values of the other rate constants
using the relationship: k−bi=([Mg2+]i·k+bi·k−bo)/([Mg2+]o·k+bo). This allowed k−bo
and δMg to be estimated independently. For the permeation model (see below), the
same principle was used to deﬁne the ion binding rate (k+bi) from the inside of the
channel.
The extracellular (k−bo (0 mV)) and intracellular (k−bi (0 mV)) unbinding
rate constants for Mg2+ from its site were kept constant when estimating the KMem
and δMem in the presence of memantine. The constant, k−bi, reﬂects Mg2+
unbinding towards the intracellular space resulting in Mg2+ permeation34,70. These
parameter estimates were then used to predict the I–V relation in the presence of
Mg2+ and memantine and the inhibition curve for memantine measured at −30
mV. Because Mg2+ block parameters could not be measured for the N615I and
V618G mutants, a single binding site, two-barrier permeation model32,33 was used
to estimate rate constants to describe the binding and permeation of Mg2+ through
the mutant channels. The net current through the channel was therefore described
by:
IMg þ INa þ IK þ ICa
¼
Mg½ i
KMgi
 
:IMax Mgi þ K½ iKKi
 
:IMaxKi  Mg½ oKMgo
 
:IMaxMgo  Na½ oKNao
 
:IMaxNao  Ca½ oKCao
 
:IMaxCao
1þ Mg½ iKMgi þ
K½ i
KKi
þ Mg½ oKMgo þ
Na½ o
KNao
þ Ca½ oKCao
ð9Þ
where for each ion, Imax is calculated by (for example):
IMax Mgi ¼ ze kbo
1þ kbiþkbokþbi
 
: Mg2þ½ i
ð10Þ
where ‘z’ is the valence of the ion and ‘e’ is the unitary charge. This allowed rate
constant values to be chosen for each ion that were consistent with the measured
NMDAR currents in normal Krebs solution and in Ca2+- or Mg2+-solutions.
Channel open probability (Popen) was predicted for the Mg2+ inhibition curves
(at −60 mV) and for the memantine inhibition curves (at −30 mV) using Eq. 4. IC50
values for the blockers were calculated from:
IC50ðMg2þ;VmÞ ¼
Mg2þ½ ikþbi Vmð Þ
 þ kbo Vmð Þð Þ þ kbi Vmð Þð Þ
kþbo Vmð Þ
ð11Þ
IC50 Memð Þ Vmð Þ ¼ 1þ
Mg2þ½ okþbo Vmð Þ
 þ Mg2þ½ ikþbi Vmð Þ 
kbo Vmð Þ þ kbi Vmð Þ
 
KMemðVmÞ
ð12Þ
All data are reported as mean± s.e.m. Statistical tests analysed the normality,
size and equality of data variances before applying parametric analysis methods. All
tests were performed on data derived from a minimum of ﬁve experiments using
an unpaired or paired Student’s t-test (as stated) or one-way analysis of variance
(ANOVA) with Dunnett’s post-hoc test when p< 0.05.
Data availability. The data that were generated in the study are available from the
corresponding authors upon reasonable request.
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